Sam Chun Dang Pharm Receives EMA Phase 1 Approval for Oral Insulin SCD0503; Pipeline Advances but Uncertainty Remains
Sam Chun Dang Pharm received EMA approval for Phase 1 clinical trial of oral insulin SCD0503. The trial will be conducted at Profil, Germany, in 64 type 1 diabetes patients to evaluate relative bioavailability and pharmacodynamics compared to subcutaneous insulin.
This approval marks a milestone for the company's oral insulin pipeline, which if successful could disrupt the injectable insulin market. However, as an early Phase 1 trial, the statistical probability of final approval is only about 10%, posing significant investment risk.
The trial is expected to conclude within 9 months (target Dec 31, 2026), with Phase 2 application to follow. Given high market expectations, stock price volatility may increase depending on trial progress and results.
[AI Comprehensive Analysis]This disclosure is a positive signal formalizing the clinical entry of Sam Chun Dang Pharm's core pipeline, oral insulin SCD0503. However, considering the early clinical stage and low success rate, the short-term positive impact should be weighed against medium- to long-term uncertainties. Given high market expectations, volatility is likely to be significant based on trial speed and outcomes.
KOSDAQ Filing Information
Filing: Investment Judgment Related Major Management Matters (Decision on Clinical Trial Plan Approval Application, etc.) (Clinical Trial to Evaluate Relative Bioavailability, Relative Biological Efficacy, and Food Effect of Oral Insulin SCD0503 Compared to Subcutaneously Administered Insulin Under Euglycemic Clamp Conditions and After Food Intake in Patients with Type 1 Diabetes Mellitus)